 Clovis Oncology Inc NASDAQ: CLVS announced a presentation detailing initial Phase 1 data from Phase 12 LuMIERE clinical study of FAP-2286 labeled with lutetium-177 177Lu-FAP-2286. Overall, in nine patients treated in the first two dose cohorts, 177Lu-FAP-2286 demonstrated. 